Cargando…

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban

Rivaroxaban has been widely used to prevent and treat various thromboembolic diseases for more than a decade. However, whether a lower dose of rivaroxaban is required for Asians is still debatable. This review aimed to explore the potential ethnic difference in pharmacokinetic/pharmacodynamic (PK/PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiao-Qin, Li, Zi-Ran, Wang, Chen-Yu, Chen, Yue-Ting, Jiao, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964148/ https://www.ncbi.nlm.nih.gov/pubmed/36839909 http://dx.doi.org/10.3390/pharmaceutics15020588

Ejemplares similares

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Kim, Minsoo, et al.
Publicado: (2019)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Ngo, Lien Thi, et al.
Publicado: (2020)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review
por: Alalawneh, Majdoleen, et al.
Publicado: (2022)

Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Erratum to: Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Single and Repeated Doses of EGb 761(®) do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
por: Hoerr, Robert, et al.
Publicado: (2022)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
por: Chong, Jia, et al.
Publicado: (2020)

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects
por: Kubitza, Dagmar, et al.
Publicado: (2014)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
por: Kubitza, Dagmar, et al.
Publicado: (2012)

Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects
por: Bratsos, Sosipatros
Publicado: (2019)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
por: Ngo, Lien Thi, et al.
Publicado: (2022)

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
por: Kubitza, Dagmar, et al.
Publicado: (2018)

Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
por: Liu, Xiao-Qin, et al.
Publicado: (2022)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
por: Willmann, Stefan, et al.
Publicado: (2013)

Initial rivaroxaban dosing in patients with atrial fibrillation
por: Ablefoni, Kaja, et al.
Publicado: (2019)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Low-dose rivaroxaban: can cardiovascular events be reduced?
por: De Luca, Leonardo
Publicado: (2023)

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
por: Moore, Kenneth T, et al.
Publicado: (2014)

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
por: Willmann, Stefan, et al.
Publicado: (2018)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
por: Zhang, Hanxu, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Rivaroxaban and Hemostasis in Emergency Care
por: Koscielny, Jürgen, et al.
Publicado: (2014)

Rivaroxaban for the Treatment of Pulmonary Embolism
por: Vanassche, Thomas, et al.
Publicado: (2013)

Rivaroxaban: Haemoptysis: case report
Publicado: (2020)

Efficacy of rivaroxaban for pulmonary embolism
por: Jia, Juan, et al.
Publicado: (2019)

The role of rivaroxaban in eosinophilic myocarditis
por: Bodagh, Carla, et al.
Publicado: (2022)

Laboratory assessment of rivaroxaban: a review
por: Samama, Meyer Michel, et al.
Publicado: (2013)

Intravesicular Onabotulinumtoxin A Hemorrhage on Rivaroxaban
por: Eubanks, Allison, et al.
Publicado: (2019)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation
por: Lee, So-Ryoung, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
por: Appeldoorn, T. Y. J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_059teerrcgqhdmt7cvpgnppj0a